Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors

Journal of Medicinal Chemistry

Volumn 59, Issue 7, 2016, Pages 3272-3302

  Kavanagh, Madeline E ^a   Coyne, Anthony G ^a   McLean, Kirsty J ^b   James, Guy G ^a   Levy, Colin W ^b   Marino, Leonardo B ^c,d   De Carvalho, Luiz Pedro S ^c   Chan, Daniel S H ^a   Hudson, Sean A ^a   Surade, Sachin ^a   Leys, David ^b   Munro, Andrew W ^b   Abell, Chris ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 121 INHIBITOR; CYTOCHROME P450 INHIBITOR; LIGAND; PHENOL; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; CYTOCHROME P-450 CYP121; CYTOCHROME P450; ENZYME INHIBITOR; PROTEIN BINDING;

ARTICLE; ASSAY; BINDING AFFINITY; MASS SPECTROMETRY; METAL BINDING; PHARMACOPHORE; ULTRAVIOLET SPECTROSCOPY; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; HUMAN; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PROTEIN TERTIARY STRUCTURE; TUBERCULOSIS;

BACTERIAL PROTEINS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; LIGANDS; MYCOBACTERIUM TUBERCULOSIS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; TUBERCULOSIS;

EID: 84966283595     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00007     Document Type: Article

References (68)

1. Global Tuberculosis Report; World Health Organisation: Geneva, 2014.
2. Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S. V.; Eiglmeier, K.; Gas, S.; Barry, C. E.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M. a; Rajandream, M. A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; Whitehead, S.; Barrell, B. G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence Nature 1998, 393, 537-544 10.1038/31159
3. McLean, K. J.; Clift, D.; Lewis, D. G.; Sabri, M.; Balding, P. R.; Sutcliffe, M. J.; Leys, D.; Munro, A. W. The preponderance of P450s in the Mycobacterium tuberculosis genome Trends Microbiol. 2006, 14, 220-228 10.1016/j.tim.2006.03.002
4. Driscoll, M. D.; McLean, K. J.; Cheesman, M. R.; Jowitt, T. A.; Howard, M.; Carroll, P.; Parish, T.; Munro, A. W. Expression and characterization of Mycobacterium tuberculosis CYP144: Common themes and lessons learned in the M. tuberculosis P450 enzyme family Biochim. Biophys. Acta, Proteins Proteomics 2011, 1814, 76-87 10.1016/j.bbapap.2010.05.015
5. Tailleux, L.; Waddell, S. J.; Pelizzola, M.; Mortellaro, A.; Withers, M.; Tanne, A.; Castagnoli, P. R.; Gicquel, B.; Stoker, N. G.; Butcher, P. D.; Foti, M.; Neyrolles, O. Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages PLoS One 2008, 3, e1403 10.1371/journal.pone.0001403
6. Holsclaw, C. M.; Sogi, K. M.; Gilmore, S. A.; Schelle, M. W.; Leavell, M. D.; Bertozzi, C. R.; Leary, J. A. Structural characterization of a novel sulfated menaquinone produced by stf3 from Mycobacterium tuberculosis ACS Chem. Biol. 2008, 3, 619-624 10.1021/cb800145r
7. McLean, K. J.; Lafite, P.; Levy, C.; Cheesman, M. R.; Mast, N.; Pikuleva, I. A.; Leys, D.; Munro, A. W. The structure of Mycobacterium tuberculosis CYP125: Molecular basis for cholesterol binding in a P450 needed for host infection J. Biol. Chem. 2009, 284, 35524-35533 10.1074/jbc.M109.032706
8. Capyk, J. K.; Kalscheuer, R.; Stewart, G. R.; Liu, J.; Kwon, H.; Zhao, R.; Okamoto, S.; Jacobs, W. R.; Eltis, L. D.; Mohn, W. W. Mycobacterial cytochrome P450 125 (Cyp125) catalyzes the terminal hydroxylation of C27 steroids J. Biol. Chem. 2009, 284, 35534-35542 10.1074/jbc.M109.072132
9. Johnston, J. B.; Kells, P. M.; Podust, L. M.; Ortiz de Montellano, P. R. Biochemical and structural characterization of CYP124: a methyl-branched lipid omega-hydroxylase from Mycobacterium tuberculosis Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 20687-20692 10.1073/pnas.0907398106
10. Gondry, M.; Sauguet, L.; Belin, P.; Thai, R.; Amouroux, R.; Tellier, C.; Tuphile, K.; Jacquet, M.; Braud, S.; Courçon, M.; Masson, C.; Dubois, S.; Lautru, S.; Lecoq, A.; Hashimoto, S.; Genet, R.; Pernodet, J.-L. Cyclodipeptide synthases are a family of tRNA-dependent peptide bond-forming enzymes Nat. Chem. Biol. 2009, 5, 414-420 10.1038/nchembio.175
11. Belin, P.; Le Du, M. H.; Fielding, A.; Lequin, O.; Jacquet, M.; Charbonnier, J.-B.; Lecoq, A.; Thai, R.; Courçon, M.; Masson, C.; Dugave, C.; Genet, R.; Pernodet, J.-L.; Gondry, M. Identification and structural basis of the reaction catalyzed by CYP121, an essential cytochrome P450 in Mycobacterium tuberculosis Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 7426-7431 10.1073/pnas.0812191106
12. McLean, K. J.; Carroll, P.; Lewis, D. G.; Dunford, A. J.; Seward, H. E.; Neeli, R.; Cheesman, M. R.; Marsollier, L.; Douglas, P.; Smith, W. E.; Rosenkrands, I.; Cole, S. T.; Leys, D.; Parish, T.; Munro, A. W. Characterization of active site structure in CYP121: A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv J. Biol. Chem. 2008, 283, 33406-33416 10.1074/jbc.M802115200
13. McLean, K. J.; Dunford, A. J.; Neeli, R.; Driscoll, M. D.; Munro, A. W. Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems Arch. Biochem. Biophys. 2007, 464, 228-240 10.1016/j.abb.2007.03.026
14. McLean, K. J.; Belcher, J.; Driscoll, M. D.; Fernandez, C. C.; Van, D. L.; Bui, S.; Golovanova, M.; Munro, A. W. The Mycobacterium tuberculosis cytochromes P450 Future Med. Chem. 2010, 2, 1339-1353 10.4155/fmc.10.216
15. Ahmad, Z.; Sharma, S.; Khuller, G. K. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis FEMS Microbiol. Lett. 2006, 261, 181-186 10.1111/j.1574-6968.2006.00350.x
16. Ahmad, Z.; Sharma, S.; Khuller, G. K. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv FEMS Microbiol. Lett. 2005, 251, 19-22 10.1016/j.femsle.2005.07.022
17. McLean, K. J.; Cheesman, M. R.; Rivers, S. L.; Richmond, A.; Leys, D.; Chapman, S. K.; Reid, G. A.; Price, N. C.; Kelly, S. M.; Clarkson, J.; Smith, W. E.; Munro, A. W. Expression, purification and spectroscopic characterization of the cytochrome P450 CYP121 from Mycobacterium tuberculosis J. Inorg. Biochem. 2002, 91, 527-541 10.1016/S0162-0134(02)00479-8
18. Ahmad, Z.; Sharma, S.; Khuller, G. K. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis Nanomedicine 2007, 3, 239-243 10.1016/j.nano.2007.05.001
19. Como, J. A.; Dismukes, W. E. Oral azole drugs as systemic antifungal therapy N. Engl. J. Med. 1994, 330, 263-272 10.1056/NEJM199401273300407
20. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51, 3661-3680 10.1021/jm8000373
21. Murray, C. W.; Rees, D. C. The rise of fragment-based drug discovery Nat. Chem. 2009, 1, 187-192 10.1038/nchem.217
22. Scott, D. E.; Coyne, A. G.; Hudson, S. A.; Abell, C. Fragment-based approaches in drug discovery and chemical biology Biochemistry 2012, 51, 4990-5003 10.1021/bi3005126
23. Hall, R. J.; Mortenson, P. N.; Murray, C. W. Efficient exploration of chemical space by fragment-based screening Prog. Biophys. Mol. Biol. 2014, 116, 82-91 10.1016/j.pbiomolbio.2014.09.007
24. Joseph-McCarthy, D.; Campbell, A. J.; Kern, G.; Moustakas, D. Fragment-based lead discovery and design J. Chem. Inf. Model. 2014, 54, 693-704 10.1021/ci400731w
25. Bollag, G.; Tsai, J.; Zhang, J.; Zhang, C.; Ibrahim, P.; Nolop, K.; Hirth, P. Vemurafenib: the first drug approved for BRAF-mutant cancer Nat. Rev. Drug Discovery 2012, 11, 873-886 10.1038/nrd3847
26. Leys, D.; Mowat, C. G.; McLean, K. J.; Richmond, A.; Chapman, S. K.; Walkinshaw, M. D.; Munro, A. W. Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 Å reveals novel features of cytochrome P450 J. Biol. Chem. 2003, 278, 5141-5147 10.1074/jbc.M209928200
27. Hudson, S. A.; McLean, K. J.; Surade, S.; Yang, Y. Q.; Leys, D.; Ciulli, A.; Munro, A. W.; Abell, C. Application of fragment screening and merging to the discovery of inhibitors of the Mycobacterium tuberculosis cytochrome P450 CYP121 Angew. Chem., Int. Ed. 2012, 51, 9311-9316 10.1002/anie.201202544
28. Hudson, S. A.; Surade, S.; Coyne, A. G.; Mclean, K. J.; Leys, D.; Munro, A. W.; Abell, C. Overcoming the limitations of fragment merging: Rescuing a strained merged fragment series targeting mycobacterium tuberculosis CYP121 ChemMedChem 2013, 8, 1451-1456 10.1002/cmdc.201300219
29. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 9997-10002 10.1073/pnas.96.18.9997
30. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 10.1016/S1359-6446(04)03069-7
31. Verdonk, M. L.; Rees, D. C. Group efficiency: A guideline for hits-to-leads chemistry ChemMedChem 2008, 3, 1179-1180 10.1002/cmdc.200800132
32. Stout, T. J.; Sage, C. R.; Stroud, R. M. The additivity of substrate fragments in enzyme-ligand binding Structure 1998, 6, 839-848 10.1016/S0969-2126(98)00086-0
33. Compton, D. R.; Sheng, S.; Carlson, K. E.; Rebacz, N. A.; Lee, I. Y.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity J. Med. Chem. 2004, 47, 5872-5893 10.1021/jm049631k
34. Johnson, M. D.; Teng, M.; Zhu, J. Aminopyrazole compounds and use as CHK1 inhibitors. WO2005/00945 A1, 2005.
35. Ciulli, A.; Williams, G.; Smith, A. G.; Blundell, T. L.; Abell, C. Probing hot spots at protein-ligand binding sites: A fragment-based approach using biophysical methods J. Med. Chem. 2006, 49, 4992-5000 10.1021/jm060490r
36. Cytochrome P450: Structure, Mechanism and Biochemistry, 3rd ed.; Ortiz de Montellano, P. R., Ed.; Kluwer Academic/Plenum Publishers: New York, 2005.
37. Glide, version 6.5; Schrödinger, LLC: New York, 2014.
38. Smith, A. J. T.; Zhang, X.; Leach, A. G.; Houk, K. N. Beyond picomolar affinities: Quantitative aspects of noncovalent and covalent binding of drugs to proteins J. Med. Chem. 2009, 52, 225-233 10.1021/jm800498e
39. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures J. Org. Chem. 1996, 61, 3849-3862 10.1021/jo960057x
40. Vasudevan, A.; Qian, Y.; Vogt, A.; Blaskovich, M. A.; Ohkanda, J.; Sebti, S. M.; Hamilton, A. D. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I J. Med. Chem. 1999, 42, 1333-1340 10.1021/jm9900873
41. Schenkman, J. B.; Remmer, H.; Estabrook, R. W. Spectral studies of drug interaction with hepatic microsomal cytochrome Mol. Pharmacol. 1967, 3, 113-123
42. Ouellet, H.; Kells, P. M.; Ortiz de Montellano, P. R.; Podust, L. M. Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1 Bioorg. Med. Chem. Lett. 2011, 21, 332-337 10.1016/j.bmcl.2010.11.007
43. McLean, K. J.; Marshall, K. R.; Richmond, A.; Hunter, I. S.; Fowler, K.; Kieser, T.; Gurcha, S. S.; Besra, G. S.; Munro, A. W. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes Microbiology 2002, 148, 2937-2949 10.1099/00221287-148-10-2937
44. Yoshida, Y.; Aoyama, Y. Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes Biochem. Pharmacol. 1987, 36, 229-235 10.1016/0006-2952(87)90694-0
45. Conner, K. P.; Woods, C.; Atkins, W. M. Interactions of cytochrome P450s with their ligands Arch. Biochem. Biophys. 2011, 507, 56-65 10.1016/j.abb.2010.10.006
46. Ouellet, H.; Podust, L. M.; Ortiz de Montellano, P. R. Mycobacterium tuberculosis CYP130: Crystal structure, biophysical characterization, and interactions with antifungal azole drugs J. Biol. Chem. 2008, 283, 5069-5080 10.1074/jbc.M708734200
47. Wheeler, S. E.; Houk, K. N. Origin of substituent effects in edge-to-face aryl-aryl interactions Mol. Phys. 2009, 107, 749-760 10.1080/00268970802537614
48. Hopkins, A. L.; Keserü, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121 10.1038/nrd4163
49. Podust, L. M.; Ouellet, H.; von Kries, J. P.; Ortiz de Montellano, P. R. Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines J. Biol. Chem. 2009, 284, 25211-25219 10.1074/jbc.M109.017632
50. Fonvielle, M.; Le Du, M. H.; Lequin, O.; Lecoq, A.; Jacquet, M.; Thai, R.; Dubois, S.; Grach, G.; Gondry, M.; Belin, P. Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121: Insights from biochemical studies and crystal structures J. Biol. Chem. 2013, 288, 17347-17359 10.1074/jbc.M112.443853
51. Munro, A. W.; Leys, D. G.; McLean, K. J.; Marshall, K. R.; Ost, T. W. B.; Daff, S.; Miles, C. S.; Chapman, S. K.; Lysek, D. A.; Moser, C. C.; Page, C. C.; Dutton, P. L. P450 BM3: the very model of a modern flavocytochrome Trends Biochem. Sci. 2002, 27, 250-257 10.1016/S0968-0004(02)02086-8
52. Duffell, K. M.; Hudson, S. A.; McLean, K. J.; Munro, A. W.; Abell, C.; Matak-Vinković, D. Nanoelectrospray ionization mass spectrometric study of Mycobacterium tuberculosis CYP121-ligand interactions Anal. Chem. 2013, 85, 5707-5714 10.1021/ac400236z
53. Driscoll, M. D.; McLean, K. J.; Levy, C.; Mast, N.; Pikuleva, I. A.; Lafite, P.; Rigby, S. E. J.; Leys, D.; Munro, A. W. Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen J. Biol. Chem. 2010, 285, 38270-38282 10.1074/jbc.M110.164293
54. Bellamine, A.; Mangla, A. T.; Nes, W. D.; Waterman, M. R. Characterization and catalytic properties of the sterol 14alpha-demethylase from Mycobacterium tuberculosis Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 8937-8942 10.1073/pnas.96.16.8937
55. McLean, K. J.; Warman, A. J.; Seward, H. E.; Marshall, K. R.; Girvan, H. M.; Cheesman, M. R.; Waterman, M. R.; Munro, A. W. Biophysical characterization of the sterol demethylase P450 from Mycobacterium tuberculosis, its cognate ferredoxin, and their interactions Biochemistry 2006, 45, 8427-8443 10.1021/bi0601609
56. Martin, D. P.; Blachly, P. G.; McCammon, J. A.; Cohen, S. M. Exploring the influence of the protein environment on metal-binding pharmacophores J. Med. Chem. 2014, 57, 7126-7135 10.1021/jm500984b
57. Copeland, R. A. Lead optimization and structure-activity relationships for reversible inhibitors. In Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, 2nd ed.; John Wiley & Sons, Inc.: Hoboken, NJ, 2013.
58. Morrison, J. F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhbitors Biochem. Biophys. Acta 1969, 185, 269-286 10.1016/0005-2744(69)90420-3
59. Hu, D. D.; Eftink, M. R. Thermodynamic studies of the interaction of trp aporepressor with tryptophan analogs Biophys. Chem. 1994, 49, 233-239 10.1016/0301-4622(93)E0073-E
60. Inhibitor screening against human cytochrome P450s was outsourced to Cyprotex Discovery Ltd., Macclesfield, Cheshire, UK.
61. Mirza, A.; Desai, R.; Reynisson, J. Known drug space as a metric in exploring the boundaries of drug-like chemical space Eur. J. Med. Chem. 2009, 44, 5006-5011 10.1016/j.ejmech.2009.08.014
62. Kim, D.; Guengerich, F. P. Cytochrome P450 activation of arylamines and heterocyclic amines Annu. Rev. Pharmacol. Toxicol. 2005, 45, 27-49 10.1146/annurev.pharmtox.45.120403.100010
63. Choi, J. Y.; Calvet, C. M.; Vieira, D. F.; Gunatilleke, S. S.; Cameron, M. D.; McKerrow, J. H.; Podust, L. M.; Roush, W. R. R-configuration of 4-aminopyridyl-based inhibitors of CYP51 confers superior efficacy against Trypanosoma cruzi ACS Med. Chem. Lett. 2014, 5, 434-439 10.1021/ml500010m
64. Choi, J. Y.; Calvet, C. M.; Gunatilleke, S. S.; Ruiz, C.; Cameron, M. D.; McKerrow, J. H.; Podust, L. M.; Roush, W. R. Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents J. Med. Chem. 2013, 56, 7651-7668 10.1021/jm401067s
65. Brennan, P. J. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis Tuberculosis 2003, 83, 91-97 10.1016/S1472-9792(02)00089-6
66. De Rossi, E.; Aínsa, J. A.; Riccardi, G. Role of mycobacterial efflux transporters in drug resistance: An unresolved question FEMS Microbiol. Rev. 2006, 30, 36-52 10.1111/j.1574-6976.2005.00002.x
67. Martin, D. P.; Blachly, P. G.; Marts, A. R.; Woodruff, T. M.; de Oliveira, C. A. F.; McCammon, J. A.; Tierney, D. L.; Cohen, S. M. Unconventional" coordination chemistry by metal chelating fragments in a metalloprotein active site J. Am. Chem. Soc. 2014, 136, 5400-5406 10.1021/ja500616m
68. Hudson, S. A.; Mashalidis, E. H.; Bender, A.; McLean, K. J.; Munro, A. W.; Abell, C. Biofragments: An approach towards predicting protein function using biologically related fragments and its application to mycobacterium tuberculosis CYP126 ChemBioChem 2014, 15, 549-555 10.1002/cbic.201300697